ANTIBODIES TO OPGL
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
1 . (canceled)
2 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises a human IgG2 heavy chain comprising the amino acid sequence of SEQ ID NO: 13, and wherein the light chain comprises a human kappa light chain comprising the amino acid sequence of SEQ ID NO: 14, and wherein the antibody interacts with an osteoprotegerin ligand (OPGL) and inhibits binding of OPGL to an osteoclast differentiation and activation receptor (ODAR).
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . The antibody of claim 2 , which is fully human.
9 . (canceled)
10 . (canceled)
11 . A pharmaceutical composition comprising an antibody of claim 2 .
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 2 from residue 20 to residue 467, and the light chain comprises an amino acid sequence of SEQ ID NO: 4 from residue 21 to residue 235, wherein the antibody interacts with an osteoprotegerin ligand (OPGL) and inhibits binding of OPGL to an osteoclast differentiation and activation receptor (ODAR).
16 . A pharmaceutical composition comprising an antibody of claim 8 .
17 . A pharmaceutical composition comprising an antibody of claim 15 .